^
    8ms
    AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Arsenal Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    cyclophosphamide • AB-2100
    10ms
    AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) (clinicaltrials.gov)
    P1/2, N=130, Not yet recruiting, Arsenal Biosciences, Inc.
    New P1/2 trial
    |
    cyclophosphamide • AB-2100
    11ms
    Development of AB-2100, an autologous integrated circuit T (ICT) cell therapy targeting CA9 intended for the treatment of ccRCC. (ASCO-GU 2024)
    These data demonstrate that AB-2100 selectively targets tumors co-expressing PSMA and CA9, and can overcome multiple suppressive mechanisms in the TME. These results support the evaluation of AB-2100 in the clinic for the treatment of advanced or metastatic ccRCC.
    IO biomarker
    |
    TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CA9 (Carbonic anhydrase 9)
    |
    FOLH1 expression • CA9 expression
    |
    AB-2100
    1year
    Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC (SITC 2023)
    Conclusions Preclinical data demonstrate that AB-2100 can selectively target antigens that cannot be safely targeted by conventional CARs, and overcome multiple suppressive mechanisms in the tumor microenvironment. These results support the evaluation of AB-2100 in the clinic for the treatment of advanced or metastatic ccRCC.
    Preclinical
    |
    FASLG (Fas ligand) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CA9 (Carbonic anhydrase 9)
    |
    FOLH1 expression • CA9 expression
    |
    AB-2100
    over1year
    A PSMA Neovasculature-Inducible CA9 CAR Resistant to FASL and TGFB Mediated Suppression for the Treatment of ccRCC (ASGCT 2023)
    Furthermore, FAS/TGFBR shRNA containing ICTs demonstrated enhanced anti-tumor activity in multiple xenograft RCC models. Collectively, these results demonstrate that PSMA x CA9 ICT cells can (i) selectively target antigens that cannot be safely targeted by conventional CARs and (ii) overcome multiple suppressive mechanisms in the tumor microenvironment.
    IO biomarker
    |
    FASLG (Fas ligand) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CA9 (Carbonic anhydrase 9)
    |
    FOLH1 expression • CA9 expression
    |
    AB-2100
    over1year
    A neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC (AACR 2023)
    Furthermore, FAS/TGFBR shRNA containing ICTs demonstrated enhanced antitumor activity in multiple xenograft RCC models. Collectively, these results demonstrate that PSMAxCA9 ICT cells can (i) selectively target antigens that cannot be safely targeted by conventional CARs and (ii) overcome multiple suppressive mechanisms in the tumor microenvironment.
    IO biomarker
    |
    FASLG (Fas ligand) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CA9 (Carbonic anhydrase 9)
    |
    FOLH1 expression • CA9 expression
    |
    AB-2100